Clinical Trial Update: Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults [Phase 3]

View source ↗

Summary

This clinical trial update reports an open-label safety extension study of vortioxetine at 15 and 20 mg for long-term treatment of adults with major depressive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11